

Section 1. Identifying Inform	ation	
1. Given Name (First Name) Lisa	2. Surname (Last Name) Rice	3. Date 13-April-2015
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Robert Lafyatis
5. Manuscript Title RAPID DECREASE IN TRANSFORMING GF IMPROVEMENT IN SYSTEMIC SCLEROSIS		GULATED BIOMARKER EXPRESSION AND CLINICAL WITH FRESOLIMUMAB
6. Manuscript Identifying Number (if you kn 77958-CMED-RV-2	ow it)	
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	est? Yes No	n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, we more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	n-Financial Other? Comments
NIH	<b>√</b>	
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descri	bed in the instructions. Uport relationships that we	nether you have financial relationships (regardless of amount less one line for each entity; add as many lines as you need by ere present during the 36 months prior to publication.
•		
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, b	proadly relevant to the work? Yes Ves



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
At the time of ma On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Cristina	2. Surname (Last Name) Padilla	3. Date 13-April-2015
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Robert Lafyatis
5. Manuscript Title RAPID DECREASE IN TRANSFORMING GI IMPROVEMENT IN SYSTEMIC SCLEROSIS		GULATED BIOMARKER EXPRESSION AND CLINICAL WITH FRESOLIMUMAB
6. Manuscript Identifying Number (if you kn 77958-CMED-RV-2	now it)	
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing	ormation below. If you have	ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial other? Comments
NIH	<b>✓</b>	
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflicts of intere	est?	
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, bi	roadly relevant to the work? Yes V No



Section 5.	elationships not covered above
	tionships or activities that readers could perceive to have influenced, or that give the appearance of ing, what you wrote in the submitted work?
Yes, the following	ng relationships/conditions/circumstances are present (explain below):
✓ No other relation	nships/conditions/circumstances that present a potential conflict of interest
At the time of manu On occasion, journa	iscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Ils may ask authors to disclose further information about reported relationships.
Section 6. D	isclosure Statement
Based on the above below.	disclosures, this form will automatically generate a disclosure statement, which will appear in the box

#### **Evaluation and Feedback**



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Sarah	2. Surname (Last Name) McLaughlin	3. Date 13-April-2015
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Robert Lafyatis
5. Manuscript Title RAPID DECREASE IN TRANSFORMING GF IMPROVEMENT IN SYSTEMIC SCLEROSIS		GULATED BIOMARKER EXPRESSION AND CLINICAL WITH FRESOLIMUMAB
6. Manuscript Identifying Number (if you kn 77958-CMED-RV-2	ow it)	
Section 2. The Work Under Co	onsideration for Public	ation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Excess rows can be removed by pressing		e more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	or-Financial other? Comments
NIH		
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Us port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes V No



Section 5.	Relationships not covered above		
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?			
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):		
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest		
At the time of ma On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.		
Section 6.	Disclosure Statement		
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box		

#### **Evaluation and Feedback**



Section 1. Identifying Inform	ation	
Given Name (First Name)  Allison	2. Surname (Last Name) Mathes	3. Date 13-April-2015
4. Are you the corresponding author?	Yes √ No	Corresponding Author's Name Robert Lafyatis
5. Manuscript Title RAPID DECREASE IN TRANSFORMING GF IMPROVEMENT IN SYSTEMIC SCLEROSIS		GULATED BIOMARKER EXPRESSION AND CLINICAL WITH FRESOLIMUMAB
6. Manuscript Identifying Number (if you kn 77958-CMED-RV-2	ow it)	
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, datest? Yes No ormation below. If you have	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation, re more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	n-Financial Other? Comments
NIH	<b>✓</b>	
Section 3. Relevant financial	at take a salaha aha	b.usissaalaule
Place a check in the appropriate boxes i of compensation) with entities as descri	bed in the instructions. Use port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, b	roadly relevant to the work? Yes V No



Section 5.	Relationships not covered above	
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?		
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):	
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest	
At the time of ma On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.	
Section 6.	Disclosure Statement	
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box	

#### **Evaluation and Feedback**



Section 1. Identifying Informa	ation		
1. Given Name (First Name) Jessica	2. Surname (Last Name) Ziemek	3. Date 13-April-2	2015
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Robert Lafyatis	
5. Manuscript Title RAPID DECREASE IN TRANSFORMING GR IMPROVEMENT IN SYSTEMIC SCLEROSIS			ND CLINICAL
6. Manuscript Identifying Number (if you known 77958-CMED-RV-2	ow it)		
Section 2			
Section 2. The Work Under Co	nsideration for Public	ation	
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing Name of Institution/Company	but not limited to grants, datest?  Yes No No No If you have the "X" button.  Grant? Personal Non	ta monitoring board, study design, manu	script preparation,
Section 3. Relevant financial a	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in of compensation) with entities as describle clicking the "Add +" box. You should repare there any relevant conflicts of interest.	bed in the instructions. Us port relationships that wer	e one line for each entity; add as mar	ny lines as you need by
Section 4. Intellectual Proper	ty Patents & Copyric	jhts	
Do you have any patents, whether plant			✓ No



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
At the time of ma On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

#### **Evaluation and Feedback**



Section 1. Ide	entifying Informa	ation					
1. Given Name (First Na Salma	ame)	2. Surnan Goummi	ne (Last Name) h			3. Date 13-April-20	015
4. Are you the correspo	onding author?	Yes	✓ No	Correspond Robert Laf	ding Author's N fyatis	Name	
5. Manuscript Title RAPID DECREASE IN IMPROVEMENT IN SY						PRESSION ANI	D CLINICAL
6. Manuscript Identifyi 77958-CMED-RV-2	ng Number (if you kno	ow it)					
Section 2.	e Work Under Co	watel away	sion for Dublic	ation			
I II							
Did you or your institut any aspect of the subm statistical analysis, etc.)	itted work (including	but not lim	nited to grants, da	a third party ta monitoring	(government, g g board, study	commercial, pri design, manusc	ivate foundation, etc.) for cript preparation,
Are there any relevar							
If yes, please fill out t Excess rows can be re				e more thar	n one entity p	oress the "ADD	" button to add a row.
Name of Institution/		Grant?	Personal Nor	n-Financial upport <mark>?</mark>	Other? C	omments	
NIH		<b>✓</b>					
Section 3. Re	levant financial	activities	outside the s	ubmitted	work.		
Place a check in the a of compensation) wi clicking the "Add +" I	th entities as descri	bed in the	instructions. Us	se one line fo	or each entity	y; add as many	(regardless of amount y lines as you need by or to publication.
Are there any relevan	nt conflicts of intere	st?	Yes ✓ No				
Section 4. Int	tellectual Proper	ty Pate	ents & Copyri	ghts			AND STATE OF THE S
Do you have any pat	ents, whether plant	ned, pend	ing or issued, br	oadly releva	ant to the wo	rk? Yes	<b>√</b> No



Costion E	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
At the time of ma On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

#### **Evaluation and Feedback**



Section 1. Identifying Inform	ation		
1. Given Name (First Name) Sashidhar	2. Surname (Last Name) Nakerakanti		3. Date 13-April-2015
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Nar Robert Lafyatis	me
5. Manuscript Title RAPID DECREASE IN TRANSFORMING GF IMPROVEMENT IN SYSTEMIC SCLEROSIS			ESSION AND CLINICAL
6. Manuscript Identifying Number (if you kn 77958-CMED-RV-2	ow it)		
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing	but not limited to grants, daest? Yes No	ta monitoring board, study de	esign, manuscript preparation,
Name of Institution/Company	Grant? Personal Nor	n-Financial Other? Con	nments
NIH	<b>/</b>		
Section 3. Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of interes	bed in the instructions. Us port relationships that we	se one line for each entity; a	add as many lines as you need by
Section 4. Intellectual Proper	rty Patents & Copyri	ghts	
Do you have any patents, whether plan	ned, pending or issued, bi	oadly relevant to the work	? ☐ Yes   ✓ No

Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

#### **Evaluation and Feedback**



Section 1. Identifying Inform	ation		
Given Name (First Name)  Michael	2. Surname (Last Name) York		3. Date 13-April-2015
4. Are you the corresponding author?	☐ Yes   ✓ No	Corresponding Author's Na Robert Lafyatis	ame
5. Manuscript Title RAPID DECREASE IN TRANSFORMING G IMPROVEMENT IN SYSTEMIC SCLEROSIS			PRESSION AND CLINICAL
<ol><li>Manuscript Identifying Number (if you kr 77958-CMED-RV-2</li></ol>	now it)		
Section 2. The Work Under Co	onsideration for Publica	ation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, data	third party (government, c a monitoring board, study d	ommercial, private foundation, etc.) for design, manuscript preparation,
Are there any relevant conflicts of intered If yes, please fill out the appropriate info Excess rows can be removed by pressin	ormation below. If you have	more than one entity pr	ress the "ADD" button to add a row.
Name of Institution/Company	Grant <sup>®</sup>	Financial Other? Co	omments
NIH	<b>√</b>		
Section 3. Relevant financial	activities outside the su	ubmitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the instructions. Use port relationships that were	one line for each entity;	; add as many lines as you need by
Are there any relevant conflicts of interest	est? Yes ✓ No		
Section 4. Intellectual Prope	rty Patents & Copyrig	hts	
Do you have any patents, whether plan	ned, pending or issued, bro	oadly relevant to the wor	k? ☐ Yes   ✓ No



Section 5.	Relationships not covered above
Are there other r potentially influe	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
At the time of ma On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Giuseppina	2. Surname (Last Name) Farina	3. Date 13-April-2015
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Robert Lafyatis
5. Manuscript Title RAPID DECREASE IN TRANSFORMING G IMPROVEMENT IN SYSTEMIC SCLEROSI		GULATED BIOMARKER EXPRESSION AND CLINICAL WITH FRESOLIMUMAB
6. Manuscript Identifying Number (if you k 77958-CMED-RV-2	now it)	
Section 2. The Work Under C	ionsideration for Public	cation
any aspect of the submitted work (includin statistical analysis, etc.)?	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of inter If yes, please fill out the appropriate inf Excess rows can be removed by pressir	formation below. If you have	ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	on-Financial Other? Comments
NIH		
Section 3. Polovant financia	l activities outside the	submitted work
Place a check in the appropriate boxes of compensation) with entities as desc	in the table to indicate wh ribed in the instructions. U eport relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Prope		
intenectual Prope	erty Patents & Copyri	
Do you have any patents, whether pla	nned, pending or issued, b	roadly relevant to the work? Yes Vo



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

#### **Evaluation and Feedback**

Section 1. Identifying Informa	ition				
<ol> <li>Given Name (First Name)</li> <li>Robert</li> </ol>	2. Surnan Spiera	ne (Last Name	)		3. Date 13-April-2015
4. Are you the corresponding author?	Yes	<b>√</b> No	Correspond Robert Laf		r's Name
<ol> <li>Manuscript Title RAPID DECREASE IN TRANSFORMING GR IMPROVEMENT IN SYSTEMIC SCLEROSIS</li> <li>Manuscript Identifying Number (if you known to the company of the company o</li></ol>	SKIN AFTE				
Section 2. The Week Under Co					
Section 2. The Work Under Co	nsiderat	tion for Puk	olication		
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)?	e paymen but not lim	t or services fronited to grants,	om a third party ( , data monitoring	(governme g board, stu	nt, commercial, private foundation, etc.) for udy design, manuscript preparation,
Are there any relevant conflicts of interes					
If yes, please fill out the appropriate information in the second of the			nave more than	one entit	ty press the "ADD" button to add a row.
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support	Other?	Comments
Rudolph Rupert Scleroderma Program at Hospital for Special Surgery.	<b>√</b>				
Novartis	$\checkmark$				
Section 3. Relevant financial a	ctivities	outside th	e submitted	work.	
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should rep	oed in the	instructions	. Use one line fo	or each en	itity; add as many lines as you need by
Are there any relevant conflicts of interes			0		
If yes, please fill out the appropriate info	rmation b	elow.			
Name of Entity	Grant?	Personal Fees?	Non-Financial Support <sup>?</sup>	Other?	Comments
Roche-Genentech	$\checkmark$				
HGS/GSK					



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Actelion	<b>√</b>					
United Therapeutics	$\checkmark$					
Chemocentryx	$\checkmark$					
BMS	$\checkmark$					
Boehringer Ingelheim		$\checkmark$				
Alexion		$\checkmark$				
Do you have any patents, whether plant	ned, pend	ling or issue		ant to the	work? Yes	✓ No
Section 5. Relationships not	covered	above				
Are there other relationships or activitie potentially influencing, what you wrote				influence	d, or that give th	e appearance of
Yes, the following relationships/conditions/circumstances are present (explain below):						
✓ No other relationships/conditions/ci						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to	ournals w o disclose	rill ask autho e further inf	ors to confirm and ormation about r	d, if neces eported r	sary, update the elationships.	ir disclosure statements
Section 6. Disclosure Stateme	ent					<b>建在欧洲</b>
Based on the above disclosures, this for below.	m will au	tomatically	generate a disclo	sure state	ement, which wil	l appear in the box

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

4



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Romy	2. Surname (Last Name) Christmann	3. Date 13-April-2015
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Robert Lafyatis
5. Manuscript Title RAPID DECREASE IN TRANSFORMING GI IMPROVEMENT IN SYSTEMIC SCLEROSIS		GULATED BIOMARKER EXPRESSION AND CLINICAL WITH FRESOLIMUMAB
6. Manuscript Identifying Number (if you kr 77958-CMED-RV-2	now it)	
Section 2. The Work Under Co	onsideration for Publi	cation
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	ive payment or services from a but not limited to grants, datest?  Yes  No ormation below. If you have	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, we more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	n-Financial Other? Comments
NIH	<b>V</b>	
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. U port relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re <b>present during the 36 months prior to publication</b> .
Section 4. Intellectual Prope	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, b	roadly relevant to the work? Yes Ves



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### **Evaluation and Feedback**



Section 1. Identifying Information	ation		
1. Given Name (First Name) Jessica	2. Surname (Last Name) Gordon		3. Date 13-April-2015
4. Are you the corresponding author?	Yes √ No	Corresponding Autho Robert Lafyatis	r's Name
<ol> <li>Manuscript Title RAPID DECREASE IN TRANSFORMING GR IMPROVEMENT IN SYSTEMIC SCLEROSIS</li> <li>Manuscript Identifying Number (if you kn) 77958-CMED-RV-2</li> </ol>	SKIN AFTER TREATMENT		
Section 2. The Work Under Co	onsideration for Public	cation	
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intered in the state of the sta	but not limited to grants, danst.  St? Yes No  Distribution below. If you have	ta monitoring board, stu	udy design, manuscript preparation,
Excess rows can be removed by pressing  Name of Institution/Company	Grant? Personal No	n-Financial other?	Comments
Kellen Foundation at Hospital for Special Surgery	✓		
Rudolph Rupert Scleroderma Program at Hospital for Special Surgery.	<b>✓</b>		
Novartis	$\checkmark$		
Section 3. Relevant financial	activities outside the	submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	bed in the instructions. Uport relationships that we	se one line for each er	ntity; add as many lines as you need by

2



Section 4.	Intellectual Property Patents & Copyrights
Do you have an	patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	owing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the ab below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

#### **Evaluation and Feedback**

Gordon



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Janice	2. Surname (Last Name) Weinberg	3. Date 13-April-2015
4. Are you the corresponding author?	Yes √ No	Corresponding Author's Name Robert Lafyatis
IMPROVEMENT IN SYSTEMIC SCLEROSIS	SKIN AFTER TREATMENT	GULATED BIOMARKER EXPRESSION AND CLINICAL WITH FRESOLIMUMAB
6. Manuscript Identifying Number (if you kn 77958-CMED-RV-2	ow it)	
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, danst.  St? Yes No  Description matter of the state of t	n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, we more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial Other? Comments
NIH	<b>/</b>	
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descri	bed in the instructions. Uport relationships that we	nether you have financial relationships (regardless of amount ise one line for each entity; add as many lines as you need by ere present during the 36 months prior to publication.
Section 4. Intellectual Proper	ty Patents & Copyri	ghts
. Do you have any patents, whether plan	ned, pending or issued, b	proadly relevant to the work? Yes Ves

Section 5.	Relationships not covered above				
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?				
Yes, the follow	Yes, the following relationships/conditions/circumstances are present (explain below):				
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest				
At the time of ma On occasion, jou	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.				
Section 6.	Disclosure Statement				
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box				

#### **Evaluation and Feedback**

Section 1. Identifying Inform	ation		
1. Given Name (First Name) Robert	2. Surname (Last Name) Lafyatis		3. Date 13-April-2015
4. Are you the corresponding author?	✓ Yes No		
<ol> <li>Manuscript Title RAPID DECREASE IN TRANSFORMING G IMPROVEMENT IN SYSTEMIC SCLEROSIS</li> <li>Manuscript Identifying Number (if you kr 77958-CMED-RV-2</li> </ol>	SKIN AFTER TREATMENT W		(PRESSION AND CLINICAL
Section 2. The Work Under Co	onsideration for Publica	ation	
Did you or your institution <b>at any time</b> receany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interesting the state of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interesting the state of th	g but not limited to grants, data est?  Yes  No ormation below. If you have	a monitoring board, study	y design, manuscript preparation,
Name of Institution/Company	Grant? Personal Non-	Financial Other?	Comments
NIH	<b>✓</b>		
Section 3. Relevant financial	activities outside the su	ubmitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re Are there any relevant conflicts of interesting the please fill out the appropriate info	ibed in the instructions. Use port relationships that were est?	e one line for each entit	ty; add as many lines as you need by
Name of Entity	Grant	-Financial other?	Comments
Genzyme/Sanofi			onsulting
Shire	<b>✓</b>	Cc	onsulting



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Regeneron	<b>✓</b>	$\checkmark$			Consulting
Biogen	<b>√</b>	$\checkmark$			Consulting
Lycera		$\checkmark$			Consulting
Novartis		$\checkmark$			Consulting
Celgene		1			Consulting
BMS	<b>✓</b>	<b>✓</b>		11	Constulting
Amira		<b>✓</b>			Consulting
Celdara		$\checkmark$			п
Celltex		$\checkmark$			.11
Dart Therapeutics		$\checkmark$			11
Idera		$\checkmark$			"
Inception	$\checkmark$	$\checkmark$		,	11
Intermune		$\checkmark$			11
Medimmune		$\checkmark$			u
Precision Dermatology	$\checkmark$	$\checkmark$			
Promedior		$\checkmark$			
Zwitter		$\checkmark$			
PRISM	$\checkmark$	$\checkmark$			
UCB	$\checkmark$	$\checkmark$			
Actelion		$\checkmark$			
EMD Serono		$\checkmark$			
Akros		$\checkmark$			
Extera		$\checkmark$			
Reneo		<b>✓</b>			
Scholar Rock		$\checkmark$			
Roche/Genentech	$\checkmark$	$\checkmark$			
HGS	$\checkmark$				
Pfizer	$\checkmark$				



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Lafyatis 4

Section 1. Identifying Info	ormation	
1. Given Name (First Name) Robert	2. Surname (Last Name) Simms	3. Date 13-April-2015
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Robert Lafyatis
5. Manuscript Title RAPID DECREASE IN TRANSFORMING IMPROVEMENT IN SYSTEMIC SCLERO		GULATED BIOMARKER EXPRESSION AND CLINICAL WITH FRESOLIMUMAB
6. Manuscript Identifying Number (if yo 77958-CMED-RV-2	u know it)	
Section 2. The Work Under	r Consideration for Public	cation
any aspect of the submitted work (includes statistical analysis, etc.)?  Are there any relevant conflicts of in	terest? Yes No information below. If you have sing the "X" button.  Grant? Personal No Fees?	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, we more than one entity press the "ADD" button to add a row.  The inancial other?  Comments
NIH		
Section 3. Relevant finance	ial activities outside the	submitted work.
of compensation) with entities as de	escribed in the instructions. U I report relationships that we terest?	nether you have financial relationships (regardless of amount see one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Name of Entity	Grant	n-Financial Other? Comments
Actelion		
Celgene		
Cytori Therapeutics	<b>✓</b>	Consulting



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments			
Reata	✓					
Bayer	$\checkmark$					
Gilead	<b>✓</b>		Consulting			
Genentech	<b>✓</b>					
Intermune						
Section 4. Intellectual Prope	rty Patents & Co <sub>l</sub>	nyriahts				
Do you have any patents, whether plan			nt to the work? Yes	✓ No		
Section 5. Relationships not	covered above					
Are there other relationships or activitie potentially influencing, what you wrote	es that readers could per in the submitted wo	perceive to have ir rk?	nfluenced, or that give the	appearance of		
Yes, the following relationships/conditions/circumstances are present (explain below):						
No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, on occasion, journals may ask authors	journals will ask autho to disclose further inf	ors to confirm and, ormation about re	, if necessary, update their ported relationships.	disclosure statements.		
Section 6. Disclosure Statem	ient					
Based on the above disclosures, this for below.	Parancia de Nobel de Artigorio de la compansión de la compansión de la compansión de la compansión de la compa	generate a disclos	ure statement, which will a	appear in the box		
				u u		



Section 1. Identifying Inform	ation		
1. Given Name (First Name) Michael	2. Surname (Last Name) Whitfield		3. Date 13-April-2015
4. Are you the corresponding author?	☐ Yes   ✓ No	Corresponding Author	or's Name
<ol> <li>Manuscript Title RAPID DECREASE IN TRANSFORMING GF IMPROVEMENT IN SYSTEMIC SCLEROSIS</li> <li>Manuscript Identifying Number (if you kn 77958-CMED-RV-2</li> </ol>	SKIN AFTER TREATMENT \		
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intereing If yes, please fill out the appropriate info Excess rows can be removed by pressing	but not limited to grants, dansts? Yes No ormation below. If you hav	ta monitoring board, st	udy design, manuscript preparation,
Name of Institution/Company	Grant? Personal Non	n-Financial Other?	Comments
NIH	<b>✓</b>		
Dr. Ralph and Marian Falk Medical Research rust	<b>✓</b>		
cleroderma Research Foundation			
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intered If yes, please fill out the appropriate info	bed in the instructions. Us port relationships that wer est?	e one line for each er	ntity; add as many lines as you need by
Name of Entity	Grant	n-Financial Other?	Comments
Celdara Medical LLC			Scientific founder

Whitfield 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.
Patent? Pending? Issued? Licensed? Royalties? Licensee? Comments
Gene expression biomarkers in SSc
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.